CHART-2 is Cardio3 BioSciences second Phase III trial for C-Cure, the first and only stem cell therapeutic using guided stem cells for the condition of congestive heart failure. C-Cure is currently in a Phase III clinical trial in Europe (CHART-1). The CHART-2 Phase III trial is a prospective, multi-centre, randomized, sham-controlled, patient- and evaluator-blinded study comparing treatment with C-Cure to a sham treatment. The trial is designed to recruit a minimum of 240 patients with chronic advanced symptomatic heart failure.
In a clinical trial, the Principal Investigator (PI) is responsible for the scientific and medical supervision of the trial. The PI reviews the protocol, oversees the implementation of the trial at all the investigational sites, and provides guidance as to the integrity and the interpretability of the data generated during the trial.
Dr Christian Homsy, CEO of Cardio3 BioSciences, said: Cardio3 BioSciences is very proud to count three such prominent physicians as the Co-Principal Investigators of its phase III clinical study for C-Cure authorized in the United States. The medical community is eagerly waiting for a solution for the treatment of heart failure patients, and CHART-2 is a promising avenue towards treating this disease. We selected three prominent cardiologists with established reputations and their acceptance to lead our clinical trial is further recognition of the potential of C-Cure as future treatment of heart failure.
*** END ***
To subscribe to Cardio3 BioSciences newsletter, visit http://www.c3bs.com. Follow us on Twitter @Cardio3Bio.
About CHART-2 CHART-2, the Company's second Phase III clinical trial, is intended to assess in the US, the efficacy of C-Cure as a treatment for heart failure of ischemic origin. CHART-2 is designed as a prospective, multi-centre, randomized, sham-controlled, patient- and evaluator-blinded study comparing treatment with C-Cure to a sham treatment. The trial is aimed to recruit a minimum of 240 patients with chronic advanced symptomatic heart failure. The primary endpoint of the trial is the Six Minute Walk Test post-procedure, a commonly used index of cardiovascular performance.
About C-Cure Cardio3 BioSciences C-Cure therapy involves taking stem cells from a patients own bone marrow and through a proprietary process called Cardiopoiesis, re-programming those cells to become heart cells. The cells, known as cardiopoietic cells, are then injected back into the patients heart through a minimally invasive procedure, with the aim of repairing damaged tissue and improving heart function and patient clinical outcomes. C-Cure is the outcome of multiple years of research conducted at Mayo Clinic (Rochester, Minnesota, USA), Cardio3 BioSciences (Mont-Saint-Guibert, Belgium) and Cardiovascular Centre in Aalst (Aalst, Belgium).
About Mayo Clinic Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a non-profit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.150years.mayoclinic.org ; http://www.mayoclinic.org ; and http://www.newsnetwork.mayoclinic.org . Mayo Clinic has a financial interest in Cardio3 Biosciences.
About Cardio3 BioSciences Cardio3BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of unmet medical needs. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium. The Companys lead product candidate C-Cure is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure consists of a patients own cells that are harvested from the patients bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis. Cardio3BioSciences has also developed C-Cathez, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium. Cardio3 BioSciences shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.
C3BS-CQR-1, C-Cure, C-Cathez, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cathezlogos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.
- Stem cell treatment after spinal cord injury: The next steps - Mayo Clinic - December 18th, 2022
- A CRISPR Alternative for Correcting Mutations That Sensitize Cells to DNA Damage - The Scientist - October 13th, 2022
- The Switch to Regenerative Medicine - Dermatology Times - October 13th, 2022
- A history of blood cancer treatment - - pharmaphorum - September 16th, 2022
- What Are Zombie Cells? Here's How They Impact Aging - Prevention Magazine - September 8th, 2022
- ThreeSixty Journalism: Be The Match works to build equity in access to bone marrow and cord blood transplants - St. Paul Pioneer Press - September 8th, 2022
- Zhang and colleagues win an $11.2 million NIH program project grant (PPG) - News - University of Alabama at Birmingham - August 22nd, 2022
- Kyle Vining: Appointment to Faculty of Penn Dental Medicine and Penn School of Engineering and Applied Science - University of Pennsylvania - August 22nd, 2022
- Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 - Business Wire - August 14th, 2022
- Engineers develop new tool that will allow for more personalized cell therapies - UMN News - July 27th, 2022
- University of Minnesota scientist responds to fraud allegations in Alzheimer's research - Star Tribune - July 27th, 2022
- Accelerating Transformational Research into Cell Transplantation for Patients with Type 1 Diabetes - UCSF - July 27th, 2022
- TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts - GuruFocus.com - July 11th, 2022
- Witt Wolfpack: Family works out fundraising and awareness after La Jollan's ALS diagnosis - La Jolla Light - July 11th, 2022
- Pluripotent stem cellderived NK cells with high-affinity noncleavable ... - July 3rd, 2022
- Life-saving lecture: Auburn student uses lessons from class to help discover father's brain tumor - Office of Communications and Marketing - June 22nd, 2022
- Bluebird's future in balance as FDA weighs gene therapy approvals - BioPharma Dive - June 13th, 2022
- Be the Match is looking for more ethnically diverse donors to help patients with blood cancers and diseases - KARE11.com - June 4th, 2022
- Minnesota woman reunites with teenager she saved through Be The Match transplant - KSTP - April 19th, 2022
- Induced Pluripotent Stem Cells and Their Potential for ... - November 22nd, 2021
- Cells or drugs? The race to regenerate the heart - Scientific American - November 8th, 2021
- Four-year-old with rare disease finally gets historic gene therapy treatment - KARE11.com - October 5th, 2021
- Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors - Stockhouse - October 5th, 2021
- EDITORIAL: The need is vast. Consider becoming an organ donor. - Yahoo News - August 18th, 2021
- Our View: The need is vast. Consider becoming an organ donor. - PostBulletin.com - August 18th, 2021
- Negrin Shines Light on the Orca-T Story in GVHD - OncLive - December 11th, 2020
- COVID-19 and the trials of treatment | News, Sports, Jobs - Escanaba Daily Press - October 16th, 2020
- NMDP/Be The Match partners with M Health Fairview and Duke University cryopreservation labs to launch Be The Match BioBank - Watauga Democrat - October 7th, 2020
- Berks County's first STEM-themed attraction opens, delights visitors young and old - Reading Eagle - October 7th, 2020
- Coronavirus Thursday update: UMN announces new stem cell ... - August 16th, 2020
- University of Minnesota launches stem cell trial against ... - August 16th, 2020
- University of Minnesota launches stem cell trial against severe COVID-19 - Minneapolis Star Tribune - August 16th, 2020
- Biotechnology Could Change the Cattle Industry. Will It Succeed? - Singularity Hub - August 16th, 2020
- Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update - Yahoo Finance - April 4th, 2020
- A word for those risking their lives amid the coronavirus crisis: Thanks - TwinCities.com-Pioneer Press - April 4th, 2020
- Coronavirus is similar to SARS and causes infection through a heart regulating enzyme: Study - International Business Times, Singapore Edition - February 4th, 2020
- Why Sangamo Therapeutics Stock Sank Today - The Motley Fool - December 13th, 2019
- Hoeven's bill supports alternative therapy for veterans with PTSD, traumatic brain injury - Ripon Advance - October 1st, 2019
- Stem-cell treatment gives two brothers a future ... - March 3rd, 2019
- The Promise of Stem Cells | Stem Cell Institute ... - August 29th, 2018
- 2018 Regenerative Medicine Minnesota Research Awards - August 17th, 2018
- FDA cracks down on stem cell clinics - CNN - August 29th, 2017
- Mayo Clinic, University of Minnesota develop 'robocop' stem cells to fight cancer - Minneapolis Star Tribune - August 24th, 2017
- Cowboy Up Ride Against Cancer - Wahpeton Daily News - August 24th, 2017
- Cargill invests in 'clean meat' start-up - KARE - August 24th, 2017
- Stem-cell clinics are using a federal website as a marketing tool for unproven treatments, U of M bioethicist says - MinnPost - July 30th, 2017
- More than 60 US clinics have sold unproven stem cell therapies for heart failure - New York Post - July 30th, 2017
- Stemonix, a stem cell research firm, wins Minnesota Cup ... - November 27th, 2016
- Minnesotas Funding of Stem Cell Research Echoes Trend ... - October 29th, 2016
- Stem cell research Experts@Minnesota - October 18th, 2016
- Stem Cell FAQs - Minnesota Regenerative Medicine - October 7th, 2016
- Minnesota invests in regenerative medicine - Health Talk - October 7th, 2016
- Minnesota to resume umbilical cord blood donations ... - September 20th, 2016
- STEM Programs - Minnesota Zoo - September 5th, 2016
- Stem Cell Treatment - Minnesota Regenerative Medicine - August 18th, 2016
- Home - Minnesota Regenerative Medicine - August 18th, 2016
- Multipotent vs. pluripotent stem cells - Pathology Student - October 19th, 2015
- 2. Bone Marrow (Hematopoietic) Stem Cells [Stem Cell ... - October 19th, 2015
- Minnesota Man With ALS Hopes Stem Cells Save His Life ... - July 2nd, 2015
- Graduate Programs - MED - Stem Cell Institute, University ... - April 26th, 2015
- Atsushi Asakura, Ph.D. - MED - Stem Cell Institute ... - March 18th, 2015
- Bioelectricity Plays Key Role in Brain Development & Repair - March 13th, 2015
- Jakub Tolar, M.D., Ph.D. - MED - Stem Cell Institute ... - February 24th, 2015
- Stem Cell Web Focus - Nature Publishing Group : science ... - February 3rd, 2015
- Family: Experimental stem-cell treatment does wonders for Gordie Howe - December 20th, 2014
- Childrens hospital gets $25M - December 16th, 2014
- Stem Cell Malaysia Blog - December 12th, 2014
- Reduction of germ cells yields more zebrafish males - December 4th, 2014
- Mayo Clinic Researchers Identify First Steps in Formation of Pancreatic Cancer - November 10th, 2014
- Anti-Cancer Drug Effective Against Common Stem Cell Transplant Complication - October 24th, 2014
- $25M gift prompts University pediatric hospital name change - October 16th, 2014
- Becoming a blood stem cell or bone marrow donor ... - October 3rd, 2014
- New heart built with stem cells - YouTube - September 27th, 2014
- Cancer Survivor Saved by Measles Virus Raises Funds for Expanded Trial - September 12th, 2014
- Researchers find animal model for understudied type of muscular dystrophy - August 30th, 2014
- Minnesota Stem Cell Therapy | Stem Cell Treatments - August 29th, 2014
- Stem Cell FAQs - MED - Stem Cell Institute, University of ... - August 22nd, 2014
- Home - MED - Stem Cell Institute, University of Minnesota - August 22nd, 2014
- Stem cells | Health Sciences - University of Minnesota - August 22nd, 2014